Top

Published in:

01-09-2012 | Original Article

Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma

Published in: Cancer Immunology, Immunotherapy | Issue 9/2012

Abstract

The production of soluble major histocompatibility complex class I–related chain A (MICA) is thought to antagonize NKG2D-mediated immunosurveillance. Interleukin-1β (IL-1β) is elevated in patients with chronic hepatitis C (CH), and this might contribute to the escape of hepatocellular carcinoma (HCC) cells from innate immunity. In this study, we investigated the immunoregulatory role of IL-1β in the production of soluble MICA of HCC cells. First, we investigated the correlation between the serum IL-1β levels and soluble MICA in CH patients. Serum IL-1β levels were associated with soluble MICA levels in CH patients. The serum IL-1β levels of CH patients with the HCC occurrence were significantly higher than those of CH patients without HCC. We next examined the MICA production of IL-1β-treated HCC cells. Addition of IL-1β resulted in significant increase in the production of soluble MICA in HepG2 and PLC/PRF/5 cells, human HCC cells. But soluble MICA was not detected in both non-treated and IL-1β-treated normal hepatocytes. Addition of IL-1β did not increase the expressions of membrane-bound MICA on HCC cells. These were observed similarly in various cancer cells including a gastric cancer (MKN1), two colon cancers (HCT116 and HT29) and a cervical cancer (HeLa). Addition of IL-1β also increased the expression of a disintegrin and metalloproteinase (ADAM)9 in HCC cells, and the knockdown of ADAM9 in IL-1β-treated HCC cells resulted in the decrease in the production of soluble MICA of HCC cells. These findings indicate that IL-1β might enhance the production of soluble MICA by activating ADAM9 in human HCC.

Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMed

Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughhan GW (1996) Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24:759–765PubMedCrossRef

Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828–833PubMedCrossRef

Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C (1992) Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264–274PubMed

Bidwell J, Keen L, Gallagher G et al (1999) Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1:3–19PubMedCrossRef

El-Omar EM, Carrington M, Chow WH et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402PubMedCrossRef

Howell WM, Calder PC, Grimble RF (2002) Gene polymorphism, inflammatory disease and cancer. Proc Nutr Soc 61:447–456PubMedCrossRef

Wang Y, Kato N, Hoshida Y et al (2003) Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37:65–71PubMedCrossRef

Tanaka Y, Furuta T, Suzuki S, Orito E, Yeo AE, Hirashima N, Sugauchi F, Ueda R, Mizokami M (2003) Impact of interleukin-1β genetic polymorphism on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J Infec Dis 187:1822–1825CrossRef

10.

Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P, Poovorawan Y (2006) Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 12:776–779PubMed

11.

Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC (2008) Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14:408–419PubMedCrossRef

12.

Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived γδT cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879–6884PubMedCrossRef

13.

Jinushi M, Takehara T, Tatsumi T et al (2003) Expression of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acids. Int J Cancer 104:354–361PubMedCrossRef

14.

Ogasawara K, Lanier LL (2005) NKG2D in NK and T cell-mediated immunity. J Clin Immunol 25:534–540PubMedCrossRef

15.

Caudert JD, Held W (2006) The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 16:333–343CrossRef

16.

Groh V, Wu J, Yee C, Spies T (2002) Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 419:734–738PubMedCrossRef

17.

Salih HR, Rammensee HG, Steinle A (2002) Downregulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098–4102PubMed

18.

Kohga K, Takehara T, Tatsumi T et al (2008) Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver disease and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 99:1643–1649PubMedCrossRef

19.

Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N (2010) Sorafenib inhibits the shedding of MICA on hepatocellular carcinoma cell by downregulating ADAM9. Hepatology 51:1264–1273PubMedCrossRef

20.

Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR (2006) Soluble MICA in malignant disease. Int J Cancer 118:684–687PubMedCrossRef

21.

Doherty DG, O’Farrelly C (2000) Innate and adaptive lymphoid cells in human liver. Immunol Rev 174:5–20PubMedCrossRef

22.

Mehal WZ, Azzaroli F, Crispe IN (2001) Immunology of the healthy liver: old questions and new insights. Gatsroenterology 120:250–260CrossRef

23.

Guerra N, Tan YX, Joncker NT et al (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28:571–580PubMedCrossRef

24.

Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N (2009) Anti-cancer chemotherapy inhibits MICA ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 69:8050–8057PubMedCrossRef

25.

Oyanagi Y, Takahashi T, Matsui S, Takahashi S, Boku S, Takahashi K, Furukawa K, Arai F, Asakura H (1999) Enhanced expression of interleukin-6 in chronic hepatitis C. Liver 19:464–472PubMedCrossRef

26.

Lapinski TW (2001) The levels of IL-1β, IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. Arch Immunol Ther Exp 49:311–316

27.

Bortolami M, Kotsafti A, Cardin R, Farinati F (2008) Fas/FasL system, IL-1β expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat 15:515–522PubMedCrossRef

28.

Migita K, Abiru S, Maeda Y et al (2005) Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Human Immunol 67:27–32CrossRef

29.

Nakagawa H, Maeda S, Yoshida H et al (2009) Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender difference. Int J Cancer 125:2264–2269PubMedCrossRef

30.

Wong VW, Yu J, Cheng AS et al (2009) High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 124:2766–2770PubMedCrossRef

31.

Waldhauer I, Goehlsdorf D, Gieseke F et al (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68:6368–6376PubMedCrossRef

32.

Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17:7–30PubMedCrossRef

33.

Yaykasli KO, Oohashi T, Hirohata S, Hatipoglu OF, Inagawa K, Demircan K, Ninomiya Y (2009) ADAMTS9 activation by interleukin 1 beta via NFATc1 in OUMS-27 chondrosarcoma cells and in human chondrocytes. Mol Cell Biochem 323:69–79PubMedCrossRef

34.

Kalinski T, Krueger S, Sel S, Wemer K, Ropke M, Roessner A (2007) ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma. Hum Pathol 38:86–94PubMedCrossRef

35.

Cai L, Zhang Z, Zhou L et al (2008) Functional impairment in circulating and intrahepatic NK cell and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129:428–437PubMedCrossRef

36.

Hassan G, Moreno S, Massimi M, Di Biagio P, Stefanini S (1997) Interleukin-1-producing plasma cells in close contact with hepatocytes in patients with chronic active hepatitis. J Hepatol 27:6–17PubMedCrossRef

37.

Gabby C, Lamacchia C, Palmer G (2010) IL-1 pathway in inflammation and human disease. Nat Rev Rheumatol 6:232–241CrossRef

Title: Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma
Publication date: 01-09-2012
Published in: Cancer Immunology, Immunotherapy / Issue 9/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1208-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2012

Animal models for IgE-meditated cancer immunotherapy

The roles of mast cells in anticancer immunity

Involvement of eosinophils in the anti-tumor response

Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth

How to connect an IgE-driven response with CTL activity?

Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization

Keynote webinar | Spotlight on antibody–drug conjugates in cancer